Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors
BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates early clinical activity and favorable safety profile in Phase 1 study as a monotherapy and in combination with Regeneron's anti-PD-1 cemiplimab.
Tumor reduction was observed in the first 6 out of 6 patients treated with BHV-1510 plus cemiplimab including confirmed partial responses
First patient dosed with Biohaven's novel, first-in-class FGFR3 directed TopoIx ADC, BHV-1530
Promising progress in the clinic demonstrates potential of Biohaven's innovative, next-generation ADC platform and TopoIx payload, with additional collaboration programs with Merus and GeneQuantum advancing preclinically.
NEW HAVEN, Conn., May 28, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today provided an update and preliminary clinical data from its oncology development programs at Biohaven's 2025 R&D Day, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. The presentation slides from Biohaven's R&D day for Oncology and its other platforms will be available on the Events and Presentations page of the Biohaven website just prior to their presentations.
Biohaven reported that its novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, demonstrated encouraging preliminary clinical activity both as a monotherapy and in combination with Regeneron's anti-PD-1 antibody cemiplimab. Early clinical data is consistent with BHV-1510's preclinical profile showing high ADC stability, differentiated safety and efficacy, immunogenic cell death, and anti-PD-1 synergism. Monotherapy tumor reductions including partial responses have been seen in patients failing standard of care therapies. The combination of BHV-1510 and cemiplimab in the ongoing Phase 1 study shows encouraging anti-tumor activity, with tumor shrinkage in the first 6 out of 6 patients treated, including confirmed partial responses and in patients with brain metastasis (Figure 1). The majority of patients treated with the combination had failed prior anti–PD-1/PD-L1 therapies. BHV-1510 showed a favorable pharmacokinetic (PK) profile, with very low levels of free payload. As monotherapy, the main toxicity observed thus far in the Phase 1 study has been stomatitis, an expected on-target Trop2 class toxicity that has been manageable. Importantly, there were no cases of payload-associated interstitial lung disease (ILD), and low rates of gastrointestinal (e.g., diarrhea) and hematologic toxicities observed. The combination with cemiplimab was well tolerated with no dose limiting toxicity to date in initial cohorts.
Nushmia Khokhar, M.D., Chief Medical Officer of Oncology at Biohaven, commented, "The early clinical data with BHV-1510 dosed in patients who failed standard of care treatment are highly encouraging, particularly the observed potential synergy with anti-PD-1 therapy. These findings, combined with the promising efficacy and tolerability profile of our novel TopoIx payload and stable linker technology, support the potential of BHV-1510 to advance into earlier lines of therapy for challenging tumor types."
Biohaven also announced the first patient has been dosed in the Phase 1 study of BHV-1530, a potential first-in-class fibroblast growth factor receptor 3 (FGFR3)-directed ADC which utilizes the proprietary Topolx payload. BHV-1530 has potential in indications of cancers driven by FGFR3 alterations and/or upregulated FGFR3 protein expression, including urothelial cancers and other solid tumors (Figure 2). FGFR3 is a clinically validated target in oncology, with one small molecule inhibitor (erdafitinib) approved. There are no FGFR3 ADCs beyond BHV-1530 advanced in clinical testing.
Michael Song, M.D., Ph.D., Principal Investigator and leading medical oncologist and hematologist at NEXT Oncology with over 22 years of experience in cancer patient care and cancer research, stated, "We are excited to partner with Biohaven and dose the first patient on this important study. This is an exciting, validated target with potential to extend therapeutic benefit to several FGFR3 driven tumors."
Biohaven is also advancing a portfolio of innovative technologies to modernize next-generation ADCs through strategic collaborations with Merus and GeneQuantum (Figure 3). The preclinical programs leverage Biohaven's differentiated ADC platform directed against undisclosed novel validated and emerging high-value targets, and incorporating the TopoIx payload that preclinically demonstrated immunogenic cell death and synergistic efficacy with PD-1/PD-L1 checkpoint inhibitors.
Brian Lestini, M.D., Ph.D., President of Oncology at Biohaven, commented, 'We are excited to be in the clinic with two innovative ADCs and to share the early clinical experience with the first of our two programs, demonstrating the potential of our oncology portfolio to deliver a wide range of optimized, next-generation ADCs. The early clinical data from the Trop2 ADC, BHV-1510, shows the predicted profile and potential of the proprietary TopoIx payload as seen preclinically, and supports broad investigation of ADCs incorporating TopoIx and highly stable linker technologies. Similarly, initiation of the first-in-human study of BHV-1530, an FGFR3 directed ADC, demonstrates the versatility of our approach to generate novel drugs with the potential to address a wide variety of unmet needs in oncology. Together with our collaborations with Merus and GeneQuantum as well as licensed conjugation technology from Yale University, Biohaven's platform has the potential to generate multiple differentiated mono- and bispecific ADC therapies with greater potency and selectivity over currently available ADC approaches."
About BiohavenBiohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Biohaven is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; MoDE™ and TRAP™ extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA; myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. For more information, visit www.biohaven.com.
Forward-looking StatementsThis news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected timing and amounts of funding under the NPA. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials, including the combination of BHV-1510 and cemiplimab in the ongoing Phase 1 study; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates and the expected timing thereof; the potential for Biohaven's product candidates to be successful therapies; and the effectiveness and safety of Biohaven's product candidates, including the safety profile of BHV-1510. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:Jennifer PorcelliVice President, Investor Relationsjennifer.porcelli@biohavenpharma.com+1 (201) 248-0741
Media Contact:Mike BeyerSam Brown Inc.mikebeyer@sambrown.com+1 (312) 961-2502
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-presents-oncology-program-updates-and-preliminary-clinical-data-showcasing-innovative-trop2-and-fgfr3-antibody-drug-conjugates-adcs-incorporating-novel-topoix-payload-with-potential-to-treat-a-wide-variety-of-tumors-302466505.html
SOURCE Biohaven Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Citi Increases PT on Oracle (ORCL), Keeps Neutral
Oracle Corporation (NYSE:ORCL) is one of the 10 software stocks analysts are upgrading. On June 12, Citi raised the price target on the company's stock to $196 from $186, while keeping a 'Neutral' rating. The firm believes that Oracle Corporation (NYSE:ORCL)'s Q4 2025 results are incrementally positive considering fiscal 2026 demand. That being said, the company's near-term earnings and FCF estimates have been falling. A team of IT professionals meticulously crafting a large-scale enterprise performance management system. As per Citi, Oracle Corporation (NYSE:ORCL) posted a strong Q4 2025, while it saw modest bookings growth. However, this was overshadowed by a strong fiscal 2026 sales outlook amidst accelerating cloud, remaining performance obligation, and total revenue growth, added the analyst. Oracle Corporation (NYSE:ORCL) expects its total cloud growth rate, applications plus infrastructure, to increase from 24% in FY 2025 to more than 40% in FY 2026. Notably, the Cloud Infrastructure growth rate is anticipated to increase from 50% in FY 2025 to more than 70% in FY 2026, while RPO is projected to grow over 100% in FY 2026. Also, Oracle Corporation (NYSE:ORCL) anticipates triple-digit MultiCloud revenue growth to continue in FY 2026. Ariel Investments, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Lastly, global leader in enterprise software, Oracle Corporation (NYSE:ORCL), traded lower alongside the broader technology sector due to macroeconomic uncertainty and in particular, the near-term prospects for artificial intelligence investment (AI) spending. As a result, ORCL reported weaker than expected quarterly earnings results. Nonetheless, management expects double-digit growth for fiscal 2026 and 2027, citing significant demand for its cloud and AI capabilities. This supports our view that ORCL's positioning as the leading provider of database software and cloud-based infrastructure is entrenched, making it a key beneficiary of global demand for generative AI development.' While we acknowledge the potential of ORCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORCL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
Yahoo
4 hours ago
- Yahoo
Zeta Global (ZETA) Jumps 12.6% on Untapped AI Opportunities
Zeta Global Holdings Corp. (NYSE:ZETA) is one of the Zeta Global Holdings rallied by 12.63 percent on Friday to end at $14.18 apiece as investors snapped up shares following a study that marketing companies are lagging behind AI execution vis-a-vis its ambitions. In its study called 'It's Time to Get Serious About AI's Business Value,' Zeta Global Holdings Corp. (NYSE:ZETA) said that while many marketing organizations have begun implementing AI, most are still in the early stages of building the data, skills and systems required to scale it effectively and realize its full enterprise potential. Based on a survey of 300 North American marketing technology decision-makers, the study found that 62 percent of organizations described their current AI deployment as 'limited' or 'moderate.' The study was viewed by investors as a huge potential and opportunity for Zeta Global Holdings Corp. (NYSE:ZETA) to tap. 'Marketing should be at the front lines of the AI revolution, but many teams are held back by fragmented data, legacy systems, and skills gaps,' said Chairman and CEO David Steinberg. A marketing manager looking at the data dashboard of a marketing automation software showing successful campaign results. 'This study reinforces what we hear every day: marketers don't need more AI promises; they need practical, scalable ways to turn AI into better performance.' While we acknowledge the potential of ZETA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Sanofi (ENXTPA:SAN) Gains FDA Approval For Dupixent To Address Rare Skin Disease
Sanofi experienced a 4% decline over the past week despite a largely unchanged market. The recent events, including the FDA approval of Dupixent for a rare skin condition and the signing of a memorandum with the Department of Health - Abu Dhabi, signal positive developments for its collaborative efforts with Regeneron and internal growth strategies. Although these announcements are significant, they were not sufficient to counteract the broader move, which might have been influenced by other factors specific to Sanofi, such as its recent €1.5 billion notes offering aimed at supporting corporate purposes. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The recent developments for Sanofi, including FDA approval of Dupixent for a rare skin condition and the memorandum with the Department of Health - Abu Dhabi, highlight efforts to enhance revenue growth through expanded market reach and innovation. Despite these positive updates, Sanofi shares experienced a 4% decline over the past week, influenced by factors such as the recent €1.5 billion notes offering. Over a longer-term period, Sanofi achieved a total shareholder return of 11.29% over five years. Comparatively, over the past year, Sanofi's performance matched the French Pharmaceuticals industry, which reported a similar decline of 5.9%. In contrast, the broader French Market fared slightly better, returning 2.2%. The recent news related to Dupixent and international partnerships could potentially boost Sanofi's revenue and earnings forecasts, providing a catalyst for future growth given the innovative pipeline and market penetration opportunities. Considering the current share price of €95.9 and the analyst consensus price target of €117.7, there is potential for an 18.5% increase, according to market projections. These developments need to be weighed against existing market conditions and company fundamentals, as analysts remain divided on future earnings prospects and valuations. Click here to discover the nuances of Sanofi with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
